Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial updating on the addition of Adavosertib to radiation therapy in patients with incurable esophageal and gastroesophageal junction cancers; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Adavosertib (adavosertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-06-08